1. How to Select Therapy In Newly Diagnosed CLL

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. IWCLL 2008 Criteria For Progressive CLL

4. Front-Line Prognostic Testing

5. FISH Testing Correlates With Outcomes

6. Factors Impacting First-Line Treatment Selection

7. Durable Responses With CIT in Young, Fit Patients Without del(17p)/TP53mut

8. CLL10 Safety Data Suggest BR is Less Toxic in Patients >65 Years

9. RESONATE-2: First-Line Ibrutinib

10. 5-Year Follow-Up of Ibrutinib

11. Anti-CD20 Combined With Chemotherapy Improves Outcomes in Unfit Patients

12. Expert Experience With Single Agent Obinutuzumab

13. Ibrutinib is Efficacious in del(17p)

14. Reduced mPFS With FCR/FC in Patients With del(17p)/TP53mut Compared With Ibrutinib

15. Outcomes Are Poor With BR in Patients With del(17p)

16. MRD Levels Might Serve as a Surrogate for Clinical Endpoints With CIT

17. Summary of Treatment Recommendations

18. Ongoing Clinical Trials

19. Abbreviations

20. Abbreviations (cont)

21. Abbreviations (cont)